AEROVIA-201 / TCP-201 — Localized Neutrophil Elastase Modulation
Program Code: SCF-CF-S12-0001
Development Status: Development Candidate Nomination Framework
Candidate Class: Inhaled Pulmonary Neutrophil Elastase Regulatory Modulator
Program: AEROVIA-CF1A
IMPORTANT DEVELOPMENT LIMITATION
A true preclinical candidate nomination requires:
- Confirmed chemical structure
- Experimental potency data
- Selectivity data
- ADME data
- Toxicology data
- Formulation data
Because these data do not exist in the current program, Stage 12 can only produce a Development Candidate Target Profile (DCTP) and nomination blueprint.
No actual drug candidate is being nominated.
I. DEVELOPMENT CANDIDATE TARGET PROFILE (DCTP)
Candidate Designation
AEROVIA-201DC
(Development Candidate Framework)
Therapeutic Class
Localized Pulmonary Elastase Regulatory Modulator
Intended Use
Adjunctive disease-modifying therapy for:
Cystic Fibrosis
II. FINAL TARGET PRODUCT PROFILE
Attribute | Target |
Route | Inhaled |
Formulation | Dry Powder Inhalation |
Dosing Frequency | Once Daily |
Therapy Duration | Chronic |
Systemic Exposure | Minimal |
Pulmonary Retention | High |
Target | Neutrophil Elastase |
Clinical Position | Add-on to CFTR modulators |
III. DEVELOPMENT CANDIDATE ARCHITECTURE
Primary Functional Component
AEROVIA-201 Core
Role:
Partial elastase modulation.
Primary objectives:
- Reduce protease injury
- Preserve host defense
- Maintain airway integrity
Supporting Functional Layer
IRD-201H
Role:
Inflammatory harmonization.
Targets:
- IL-8
- TNF-α
- NF-κB
ECM-201P
Role:
Structural preservation.
Targets:
- ECM integrity
- Elastin preservation
- MMP regulation
NRF-201R
Role:
Redox support.
Targets:
- Oxidative stress
- Mitochondrial resilience
IV. DEVELOPMENT CANDIDATE PROFILE
Desired Pharmacology
Parameter | Goal |
Elastase modulation | Partial |
Protease selectivity | High |
Host-defense preservation | Required |
ECM preservation | Required |
Inflammatory harmonization | Required |
Desired PK
Parameter | Goal |
Lung Tmax | <2 h |
Lung Half-Life | 8–24 h |
Lung/Plasma Ratio | High |
Systemic Exposure | Low |
Accumulation Risk | Low |
Desired Safety
Endpoint | Goal |
Pulmonary irritation | Minimal |
Bronchospasm | Minimal |
Cytotoxicity | Minimal |
Immunosuppression | Avoid |
Chronic-use compatibility | Required |
V. PRECLINICAL DEVELOPMENT PACKAGE
Module A — Pharmacology
Required Deliverables:
Target Validation
- Elastase engagement
- Protease selectivity
Cellular Validation
- CF airway epithelial models
- Barrier function assays
- Cytokine profiling
Functional Validation
- ECM protection
- Elastin degradation reduction
Module B — PK
Required Deliverables:
Pulmonary PK
- Lung concentration
- Residence time
- Lung/plasma ratio
PD
- Elastase biomarkers
- MMP biomarkers
- IL-8 biomarkers
Module C — Safety
Required Deliverables:
Acute Pulmonary Safety
- Airway reactivity
- Histopathology
- BAL analysis
Repeat-Dose Safety
- 28-day inhalation studies
- Exploratory chronic studies
VI. CMC DEVELOPMENT PACKAGE
Drug Substance
Requirements:
- Scalable synthesis
- Defined impurity profile
- Stability characterization
Drug Product
Primary:
Dry Powder Inhalation
Backup:
Nebulized Liposomal Formulation
Manufacturing Readiness
Required:
- Process chemistry package
- Analytical methods
- Stability program
- Pilot manufacturing batches
VII. TRANSLATIONAL PACKAGE
Patient Selection Strategy
Cohort A
Patients receiving:
Trikafta
with residual inflammation.
Cohort B
Advanced lung disease.
Cohort C
Rare mutation populations.
VIII. BIOMARKER PACKAGE
Tier 1
Target Engagement
Marker | Purpose |
Elastase | Primary |
MMP-9 | Secondary |
Elastin fragments | Structural preservation |
Tier 2
Inflammatory Burden
Marker | Purpose |
IL-8 | Cytokine activity |
TNF-α | Inflammatory burden |
CRP | Systemic inflammation |
Tier 3
Clinical Translation
Endpoint | Purpose |
FEV1 | Lung function |
LCI | Disease modification |
Exacerbation rate | Clinical efficacy |
IX. IND-ENABLING BLUEPRINT
Required Studies
Pharmacology
- Mechanism confirmation
- Dose-response studies
Toxicology
- Rodent inhalation
- Non-rodent inhalation
Safety Pharmacology
- Respiratory
- Cardiovascular
- CNS
CMC
- GMP manufacturing readiness
X. REGULATORY PACKAGE
FDA Strategy
Potential designations:
- Orphan Drug Designation
- Fast Track Designation
Potential future consideration:
- Breakthrough Therapy Designation
if supported by clinical evidence.
XI. SCF DEVELOPMENT CANDIDATE SCORECARD
Domain | Status |
Disease rationale | Complete |
Pathway alignment | Complete |
Ethnobioprospecting | Complete |
Translational strategy | Complete |
Formulation strategy | Complete |
Candidate structure | Not Yet Available |
Experimental validation | Not Yet Available |
Candidate nomination | Not Yet Available |
XII. STAGE 12 DECISION
Current Program Status
Development Candidate Framework Complete
Actual Candidate Nomination
Not possible until:
- Lead structure identified.
- Potency confirmed.
- Selectivity confirmed.
- PK characterized.
- Safety established.
STAGE 12 OUTCOME
READY FOR STAGE 13
STAGE 13 — EXPERIMENTAL HIT VALIDATION, LEAD NOMINATION & IND-ENABLING EXECUTION
Stage 13 transitions the program from conceptual design into evidence-generating development.
Required outputs:
- Hit validation package
- Lead nomination package
- SAR dataset
- PK dataset
- Toxicology dataset
- Candidate selection report
- IND-enabling execution plan
Progression beyond this stage requires real experimental pharmacology and medicinal chemistry data.
MASTER REGISTRY INDEX
SCF-CF-S12-0001 — Development Candidate Package
SCF-CF-AEROVIA201-DC — Development Candidate Target Profile
SCF-CF-API-201 — Pulmonary Neutrophil Elastase Modulator Program
SCF-HITDISC-0001 — Hit Discovery Framework
SCF-SAR-0001 — Structure–Activity Relationship Framework
SCF-ADME-0001 — ADME Optimization Framework
SCF-PKPD-0001 — Pharmacokinetic & Pharmacodynamic Framework
SCF-CMC-0001 — Chemistry, Manufacturing & Controls Framework
SCF-FDA-IND-0001 — Translational Development Framework
SCF-SEF-MD-0001 — Synergistic Evaluation Framework